Can the popular vaccine FluMist make a comeback in the U.S.?

This week could be pivotal for the fate of the popular influenza vaccine known as FluMist and its manufacturer MedImmune, a division of AstraZeneca.

On Wednesday, the Advisory Committee on Immunization Practices will hear a pitch the company hopes will persuade it to restore its recommendation for use of FluMist, the only non-injectable flu vaccine licensed in the United States.

The panel declined to offer its backing of FluMist for the last two years because of concerns it isn’t protecting against H1N1 flu viruses. That effectively sidelined the vaccine here for the current and the previous flu seasons.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In